Here’s the translation to American English:
—
On the occasion of World Alzheimer’s Day, which will be celebrated on September 21, Dr. Gurutz Linazasoro, a neurologist at Policlínica Gipuzkoa, has shared an optimistic message about the advances in the diagnosis and treatment of this neurodegenerative disease. Linazasoro emphasizes that, after 40 years in practice, he has seen significant evolution in the options available for patients.
“In the past, we had virtually nothing to offer people with Alzheimer’s, but today we have treatments that not only improve symptoms but, in the near future, will bring to Spain medications that act directly on the disease’s origin: the deposits of amyloid protein,” the specialist states.
The new treatments, which are already available in the United States and England, have proven effective in eliminating amyloid deposits from the brain, allowing for a slowdown in the progression of the disease and making it less severe. “This marks a before and after in Alzheimer’s treatment. The great goal has always been to modify the course of the disease and buy time against neurodegeneration,” adds Linazasoro.
The specialist also highlights innovations in diagnosis: “Today, it is possible to detect these intracerebral deposits through a simple blood test, opening the door to earlier and more effective interventions.”
With such a promising outlook, Linazasoro sends a message of optimism to affected families and patients: “We are at the first station of a long journey that will lead us toward the prevention of Alzheimer’s disease. The scientific foundations are solid, and we are excited about what is to come. Until then, I encourage everyone to keep hope alive.”
Policlínica Gipuzkoa has become a reference center in Alzheimer’s research, pioneering participation in clinical trials designed to slow the progression of the disease and improve the quality of life for its patients. With over three decades of experience, the Advanced Therapies Unit in Parkinson’s and Alzheimer’s, led by Linazasoro, has involved more than a thousand participants in various international clinical trials.
This Guipuzkoan hospital, part of the Quirónsalud Group, has the necessary infrastructure and specialized team to carry out research with a high level of scientific rigor. Its commitment has strengthened Policlínica Gipuzkoa as a valuable member in the network of centers recognized by international research sponsors, actively contributing to advancements that will shape the future of Alzheimer’s treatment.
via: MiMub in Spanish
